HCPLive
American Heart Association 2013 Scientific Sessions

American Heart Association 2013 Scientific Sessions | AHA 2013

The AHA 2013 Scientific Sessions "is the leading cardiovascular meeting for basic, translational, clinical and population science, in the United States," and is designed to "improve patient care by communicating the most timely and significant advances in prevention, diagnosis and treatment of cardiovascular disease from many different perspectives."

Conference Coverages

Study Looks at Effect of Vitamin D Deficiency on Treatment for Hypertension
Study Looks at Effect of Vitamin D Deficiency on Treatment for Hypertension
With nearly one-third of US adults suffering from vitamin D deficiency, and studies showing a strong association between vitamin D deficiency and hypertension risk, supplementation with vitamin D may increase the effectiveness of hypertension treatments.
Aspirin at Bedtime vs. Aspirin in the Morning: Which Produces Greater Cardiovascular Benefits?
Although there appears to be no difference in blood pressure reduction in patients who take aspirin at bedtime compared to those who take it when they awake in the morning, bedtime aspirin may be associated with reduced morning platelet reactivity.
Ticagrelor Prescribed Less Frequently than other Antiplatelet Agents Overall, but Used More Often in Higher-Risk Patients
A recent study of thienopyridine use among patients who had undergone percutaneous coronary intervention (PCI) in a large hospital network found that the antiplatelet drug ticagrelor was more frequently prescribed in higher risk, less stable patients.
Effect of Proton Pump Inhibitor Use on Risk of CV Events in Patients Treated with Rivaroxaban and a Thienopyridine
Treatment with rivaroxaban reduced the long-term risk of cardiovascular death, myocardial infarction, or stroke in patients with ACS on a thienopyridine such as clopidogrel, regardless of PPI use.
Bioengineered Blood Vessel Offers Potential Improvements for Dialysis Patients
Initial results from human clinical trials involving the use of bioengineered blood vessels could point the way to cost-effective alternative therapies for hemodialysis patients with end-stage renal disease.

Most Popular

$vacMongoViewPlus$ $vAR$